{"id":17333,"date":"2013-11-27T06:30:00","date_gmt":"2013-11-27T05:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/roche-17-monte-salari-in-svizzera\/"},"modified":"2013-11-27T06:30:00","modified_gmt":"2013-11-27T05:30:00","slug":"roche-17-monte-salari-in-svizzera","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/roche-17-monte-salari-in-svizzera\/","title":{"rendered":"Roche, +1.7% wage bill in Switzerland"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\"><span style=\"font-family: BookAntiqua; color: #212120; font-size: 14pt; mso-bidi-font-family: BookAntiqua\"><font face=\"Calibri\">&quot;The global drug market maintains attractive growth rates and in 2016 is expected to reach the value of 1,200 billion dollars, but growth will mainly be supported by emerging markets, specialty pharmaceuticals and the generics segment. Big Pharma will have to continue to adapt in an increasingly complex ecosystem&quot;. Sergio Liberatore, managing director of ImsHealth, summed up the scenario of the challenge that pharmaceutical companies will have to face, on the occasion of the meeting &#039;Innovating to grow - Challenges and opportunities for the health system with respect to changes in the social scenario&#039; in Tirrenia. We can already see some examples, adds Liberatore: &quot;The ranking of the top 10 companies on the market \u2013 he underlines \u2013 has remained substantially stable, but the search for balance for the &#039;top ten&#039; is increasingly complex: in 2004 they absorbed 51% from the market, in 2012 they dropped to 47%&quot;.<\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; margin: 0cm 0cm 10pt\"><i><span style=\"line-height: 115%; font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; color: #212120; font-size: 9pt; mso-bidi-font-weight: bold\">March 25, 2013 \u2013 PharmaKronos<\/p>\n<p><\/span><\/i><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: left\">&nbsp; <img","protected":false},"excerpt":{"rendered":"<p>&quot;Il mercato mondiale dei farmaci mantiene tassi di crescita interessanti e nel 2016 dovrebbe toccare il valore di 1.200 miliardi di dollari, ma a sostenere la crescita saranno principalmente i mercati emergenti, la farmaceutica specialistica e il segmento dei generici. Le Big Pharma dovranno continuare ad adeguarsi in un ecosistema sempre pi&ugrave; complesso&quot;. A riassumere &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-17333","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=17333"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17333\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=17333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=17333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=17333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}